Yazar "Lotti, Torello" seçeneğine göre listele

Listeleniyor 1 - 4 / 4
  • Küçük Resim Yok
    Öğe
    Cutaneous and Allergic reactions due to COVID-19 vaccinations: A review
    (Wiley, 2022) Temiz, Selami Aykut; Abdelmaksoud, Ayman; Wollina, Uwe; Kutlu, Omer; Dursun, Recep; Patil, Anant; Lotti, Torello
    Introduction The pandemic caused by the novel coronavirus disease 2019 (COVID-19) has had an unprecedented impact on the overall health and the global economy. Vaccination is currently the most dependable strategy to end the pandemic, despite the slower-than-hoped-for rollout, particularly for low-to-middle-income countries, and the uncertain duration of protection afforded by vaccination. The spike protein of the virus (immunodominant antigen of the virus) is the main target of the approved and candidate SARS-CoV-2 vaccines. This protein binds to the ACE2 receptor of the host cell, initiating the entry of the virus into the cell and the chain of subsequent events ending to Acute Respiratory Distress Syndrome. The safety profile of these vaccines needs is closely assessed. Methods This comprehensive review includes searching the PubMed, EMBASE, and Web of Science databases using the keywords coronavirus, COVID-19, vaccine, cutaneous reactions, allergic reactions, and SARS-CoV-2. Manual searching of reference lists of included articles augmented the research. The research was updated in June 2021. Results In this narrative review, we tried to investigate and discuss the cutaneous and allergic reactions related to SARS-CoV-2 vaccines currently available in the literature. As a result, although COVID-19 vaccines can be reported to develop allergic and anaphylactic reactions, especially after m-RNA vaccines, they remain at a low rate, and it is observed that these reactions may develop more frequently, especially in patients with previous allergies and mast cell disorders. Fortunately, these reactions are generally transient, benign, self-limited. Conclusion Although there is still no definitive evidence, as dermatologists, we must be aware of the possibility of cutaneous reactions, newly diagnosed dermatoses, or exacerbation of existing dermatoses that may develop after the COVID-19 vaccinations.
  • Küçük Resim Yok
    Öğe
    Isotretinoin and pregnancy termination: an overview
    (Wiley, 2023) Abdelmaksoud, Ayman; Wollina, Uwe; Lotti, Torello; Temiz, Selami A.
    [Abstract Not Availabe]
  • Küçük Resim Yok
    Öğe
    Isotretinoin-induced hair disorders in the era of COVID-19 and related vaccines: A case series
    (Wiley, 2022) Abdelmaksoud, Ayman; Temiz, Selami Aykut; Dursun, Recep; Wollina, Uwe; Rudnicka, Lidia; Isik, Begum; Lotti, Torello
    [Abstract Not Availabe]
  • Küçük Resim Yok
    Öğe
    Treatment considerations for Behcet disease in the era of COVID-19: A narrative review
    (Wiley, 2021) Elmas, Omer Faruk; Demirbas, Abdullah; Bagcier, Fatih; Tursen, Umit; Atasoy, Mustafa; Dursun, Recep; Lotti, Torello
    COVID-19 is a multisystem disease caused by severe acute respiratory syndrome coronavirus 2. It has been declared a pandemic by the World Health Organization in March 2020 and the outbreak still keeps its impacts worldwide. Behcet disease (BD) is a multi-systemic vasculitis involving the skin, mucosa, eyes, joints, nervous system, cardiovascular system, and gastrointestinal system. The precise etiopathogenesis of the disorder is unknown but autoimmunity is believed to play a key role. A considerable part of patients with BD are susceptible to immunosuppression and are more predisposed to infections than healthy individuals. Hence, the protection and control measures for patients with BD against the COVID-19 are of the utmost significance. Given the requirement to balance proper treatment of BD with the smallest risk of COVID-19 associated mortality and morbidity, we aimed to review the management of BD in the era of the pandemic with a special focus on treatment considerations. According to current expert recommendations, there is no reason to discontinue topical treatments, colchicine, and nonsteroidal antiinflammatory drugs. Systemic steroids can be used at the lowest possible dose if needed. Ongoing treatments can be continued unchanged in patients with no suspected or confirmed COVID-19. In cases with COVID-19 symptoms, immunosuppressive and biological agents can be temporarily stopped but the decision should be made on a case by case basis. Considering their potential beneficial effects on the course of COVID-19, colchicine, pentoxifylline, and dapsone can be considered as safe treatment options in BD.